Literature DB >> 29498020

Botulinum Toxin: Does it have a Place in the Management of Depression?

Matthew V Rudorfer1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29498020     DOI: 10.1007/s40263-018-0491-y

Source DB:  PubMed          Journal:  CNS Drugs        ISSN: 1172-7047            Impact factor:   5.749


× No keyword cloud information.
  10 in total

1.  Botulinum toxin for depression: Does patient appearance matter?

Authors:  Jason S Reichenberg; Aaron J Hauptman; Henry T Robertson; Eric Finzi; Tillman H C Kruger; M Axel Wollmer; Michelle Magid
Journal:  J Am Acad Dermatol       Date:  2016-01       Impact factor: 11.527

2.  The link between facial feedback and neural activity within central circuitries of emotion--new insights from botulinum toxin-induced denervation of frown muscles.

Authors:  Andreas Hennenlotter; Christian Dresel; Florian Castrop; Andres O Ceballos-Baumann; Andres O Ceballos Baumann; Afra M Wohlschläger; Bernhard Haslinger
Journal:  Cereb Cortex       Date:  2008-06-17       Impact factor: 5.357

3.  Facing depression with botulinum toxin: a randomized controlled trial.

Authors:  M Axel Wollmer; Claas de Boer; Nadeem Kalak; Johannes Beck; Thomas Götz; Tina Schmidt; Muris Hodzic; Ursula Bayer; Thilo Kollmann; Katja Kollewe; Daniela Sönmez; Katja Duntsch; Martin D Haug; Manfred Schedlowski; Martin Hatzinger; Dirk Dressler; Serge Brand; Edith Holsboer-Trachsler; Tillmann H C Kruger
Journal:  J Psychiatr Res       Date:  2012-02-24       Impact factor: 4.791

4.  Treatment of depression with botulinum toxin A: a case series.

Authors:  Eric Finzi; Erika Wasserman
Journal:  Dermatol Surg       Date:  2006-05       Impact factor: 3.398

5.  Emotional proprioception: Treatment of depression with afferent facial feedback.

Authors:  Eric Finzi; Norman E Rosenthal
Journal:  J Psychiatr Res       Date:  2016-06-16       Impact factor: 4.791

6.  Treatment of depression with onabotulinumtoxinA: a randomized, double-blind, placebo controlled trial.

Authors:  Eric Finzi; Norman E Rosenthal
Journal:  J Psychiatr Res       Date:  2013-12-01       Impact factor: 4.791

7.  Treatment of major depressive disorder using botulinum toxin A: a 24-week randomized, double-blind, placebo-controlled study.

Authors:  Michelle Magid; Jason S Reichenberg; Poppy E Poth; Henry T Robertson; Amanda K LaViolette; Tillmann H C Kruger; M Axel Wollmer
Journal:  J Clin Psychiatry       Date:  2014-08       Impact factor: 4.384

Review 8.  The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis.

Authors:  Samuel T Wilkinson; Elizabeth D Ballard; Michael H Bloch; Sanjay J Mathew; James W Murrough; Adriana Feder; Peter Sos; Gang Wang; Carlos A Zarate; Gerard Sanacora
Journal:  Am J Psychiatry       Date:  2017-10-03       Impact factor: 18.112

9.  Agitation predicts response of depression to botulinum toxin treatment in a randomized controlled trial.

Authors:  M Axel Wollmer; Nadeem Kalak; Stefanie Jung; Claas de Boer; Michelle Magid; Jason S Reichenberg; Serge Brand; Edith Holsboer-Trachsler; Tillmann H C Kruger
Journal:  Front Psychiatry       Date:  2014-03-31       Impact factor: 4.157

10.  Depression in blepharospasm: a question of facial feedback?

Authors:  Janis Rebecca Bedarf; Sied Kebir; Joan Philipp Michelis; Bettina Wabbels; Sebastian Paus
Journal:  Neuropsychiatr Dis Treat       Date:  2017-07-14       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.